FKBPL Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

FKBPL Polyklonal Antikörper für WB, IHC, FC (Intra), IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human und mehr (2)

Anwendung

WB, IHC, FC (Intra), IP, ChIP, ELISA, IF

Konjugation

Unkonjugiert

Publikationen

21

Kat-Nr. : 10060-1-AP

Synonyme

WISp39, WAF-1/CIP1 stabilizing protein 39, NG7, FK506-binding protein-like, DIR1

---

Galerie der Validierungsdaten

• 

  WB analysis of HEK-293 using 10060-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10060-1-AP (FKBPL antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 10060-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 10060-1-AP (FKBPL antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human brain using 10060-1-AP

  human brain tissue were subjected to SDS PAGE followed by western blot with 10060-1-AP (FKBPL antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human testis using 10060-1-AP

  human testis tissue were subjected to SDS PAGE followed by western blot with 10060-1-AP (FKBPL antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 10060-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10060-1-AP (FKBPL antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  IP experiment of MCF-7 using 10060-1-AP

  IP result of anti-FKBPL (IP:10060-1-AP, 3ug; Detection:10060-1-AP 1:800) with MCF-7 cells lysate 2500ug.

• 

  IHC staining of human breast cancer using 10060-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 10060-1-AP (FKBPL antibody) at dilution of 1:600 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 10060-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 10060-1-AP (FKBPL antibody) at dilution of 1:600 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human testis using 10060-1-AP

  Immunohistochemical analysis of paraffin-embedded human testis tissue slide using 10060-1-AP (FKBPL antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human testis using 10060-1-AP

  Immunohistochemical analysis of paraffin-embedded human testis tissue slide using 10060-1-AP (FKBPL antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  FC experiment of HeLa using 10060-1-AP

  1x10^6 HeLa cells were intracellularly stained with 0.4 ug FKBPL Polyclonal antibody (10060-1-AP) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.4 ug Rabbit IgG control Rabbit PolyAb (30000-0-AP) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HEK-293-Zellen, HeLa-Zellen, humanes Hirngewebe, humanes Hodengewebe, Jurkat-Zellen, MCF-7-Zellen, MDA-MB-453s-Zellen, T-47D-Zellen
• Erfolgreiche IP: MCF-7-Zellen
• Erfolgreiche Detektion in IHC: humanes Mammakarzinomgewebe, humanes Hodengewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in FC (Intra): HeLa-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:4000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:300-1:1200
• Durchflusszytometrie (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 3 publications below
• WB: See 18 publications below
• IHC: See 7 publications below
• IF: See 8 publications below
• ChIP: See 1 publications below

Produktinformation

10060-1-AP bindet in WB, IHC, FC (Intra), IP, ChIP, ELISA, IF FKBPL und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: FKBPL fusion protein Ag0112
• Vollständiger Name: FK506 binding protein like
• Berechnetes Molekulargewicht: 349 aa, 38 kDa
• Beobachtetes Molekulargewicht: 42-48 kDa
• GenBank-Zugangsnummer: BC004168
• Gene symbol: FKBPL
• Gene ID (NCBI): 63943
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

FKBPL, also named as DIR1, NG7 and WISp39, has similarity to the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking. FKBPL levels may be a prognostic indicator and determinant of response to endocrine therapy(PMID:20103631, 15664193). It can be detected the band between 38 kDa and 48 kDa by western blot.

Publikationen

Species	Application	Title
human,mouse	WB,IF	J Adv Res; Hsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy; Authors - Jia-Jie Lin
human	WB	Cancer Res; FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.; Authors - McKeen Hayley D HD
human	IF	Cell Mol Life Sci; A placenta-on-a-chip model to determine the regulation of FKBPL and galectin-3 in preeclampsia; Authors - Sahar Masoumeh Ghorbanpour
human	WB	J Control Release; Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.; Authors - Eoghan J Mulholland ; KD Validated
human	WB,IHC	Clin Cancer Res; FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.; Authors - Valentine Andrea A
human	WB, ChIP	Oncogene; Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.; Authors - C Donley